Format:
Online-Ressource
ISSN:
1757-4684
Content:
Opportunities to treat infection with hepatitis C virus (HCV) are evolving rapidly. From the introduction of interferon-α monotherapy in 1992 to the approval of telaprevir- and boceprevir-based triple therapies with pegylated interferon-α and ribavirin in 2011, the chances of curing patients infected with HCV genotype 1 have improved from 〈10% to approximately 70%. ...
In:
European Molecular Biology Organization, EMBO molecular medicine, Weinheim : Wiley-VCH, [2009]-, Band 6, Heft 1 (2014), Seite 4-15, 1757-4684
In:
volume:6
In:
year:2014
In:
number:1
In:
pages:4-15
Language:
English
DOI:
10.1002/emmm.201303131
URN:
urn:nbn:de:hebis:30:3-347134